Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.43 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.43 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8489977 | 0.85 | HSD17B3 (0.53) | HSD17B3MAPTGAAALDH1A1ERAP1 | |
| SCHEMBL8490526 | 0.83 | HSD17B3 (0.52) | HSD17B3GAAALDH1A1ERAP1PPARG | |
| SCHEMBL8489446 | 0.81 | HSD17B3 (0.50) | HSD17B3MAPTGAAALDH1A1ERAP1 | |
| SCHEMBL8491511 | 0.81 | HSD17B3 (0.50) | HSD17B3MAPTGAAALDH1A1ERAP1 | |
| SCHEMBL6277138 | 0.81 | MAP1LC3B (0.53) | HSD17B3GAAALDH1A1ERAP1PPARG | |
| SCHEMBL8489872 | 0.81 | MAP1LC3B (0.53) | HSD17B3GAAALDH1A1ERAP1PPARG | |
| SCHEMBL6277201 | 0.81 | MAP1LC3B (0.53) | HSD17B3GAAALDH1A1ERAP1PPARG | |
| SCHEMBL8488462 | 0.81 | MAP1LC3B (0.53) | HSD17B3GAAALDH1A1ERAP1PPARG | |
| SCHEMBL8488403 | 0.80 | MAP1LC3B (0.53) | HSD17B3MAPTGAAALDH1A1ERAP1 | |
| SCHEMBL8494490 | 0.79 | HSD17B3 (0.47) | HSD17B3GAAALDH1A1ERAP1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754480-B1 | Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers | UNIV NORTH CAROLINA (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7713949-B2 | Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1754480-A2 | Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1379235-B1 | COMPOSITIONS AND METHODS FOR ENHANCING PARACELLULAR PERMEABILITY ACROSS EPITHELIAL AND ENDOTHELIAL BARRIERS | UNIV NORTH CAROLINA (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1379235-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PARACELLULAR PERMEABILITY ACROSS EPITHELIAL AND ENDOTHELIAL BARRIERS | University of North Carolina at Chapel Hill et al. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20020115641-A1 | Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers | THAKKER DHIREN R (US) | 2002-08-22 | — | — | US | disclosed |
| WO-2002030408-A2 | COMPOSITIONS COMPRISING PHOSPHOLIPASE C INHIBITORS AND METHODS FOR ENHANCING PARACELLULAR PERMEABILITY ACROSS EPITHELIAL AND ENDOTHELIAL BARRIERS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115641-A1 | Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers | LIPG, FABP2, PLA2G2A | HSD17B3 1851/4885MAPT 4428/4885GAA 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.